S&P 500   4,960.70 (-0.30%)
DOW   38,489.57 (-0.19%)
QQQ   423.61 (-0.87%)
AAPL   181.54 (-0.01%)
MSFT   399.30 (-0.87%)
META   466.61 (-0.98%)
GOOGL   141.99 (+0.62%)
AMZN   167.76 (+0.41%)
TSLA   193.02 (-0.38%)
NVDA   674.10 (-2.94%)
NIO   6.06 (+1.68%)
AMD   162.79 (-1.75%)
BABA   75.81 (+3.65%)
T   16.98 (+0.41%)
F   12.13 (-0.98%)
MU   80.29 (-0.52%)
CGC   3.35 (-5.37%)
GE   148.36 (-0.17%)
DIS   108.02 (-1.30%)
AMC   4.61 (-1.07%)
PFE   27.53 (-0.22%)
PYPL   57.89 (-1.26%)
XOM   104.47 (+1.67%)
S&P 500   4,960.70 (-0.30%)
DOW   38,489.57 (-0.19%)
QQQ   423.61 (-0.87%)
AAPL   181.54 (-0.01%)
MSFT   399.30 (-0.87%)
META   466.61 (-0.98%)
GOOGL   141.99 (+0.62%)
AMZN   167.76 (+0.41%)
TSLA   193.02 (-0.38%)
NVDA   674.10 (-2.94%)
NIO   6.06 (+1.68%)
AMD   162.79 (-1.75%)
BABA   75.81 (+3.65%)
T   16.98 (+0.41%)
F   12.13 (-0.98%)
MU   80.29 (-0.52%)
CGC   3.35 (-5.37%)
GE   148.36 (-0.17%)
DIS   108.02 (-1.30%)
AMC   4.61 (-1.07%)
PFE   27.53 (-0.22%)
PYPL   57.89 (-1.26%)
XOM   104.47 (+1.67%)
S&P 500   4,960.70 (-0.30%)
DOW   38,489.57 (-0.19%)
QQQ   423.61 (-0.87%)
AAPL   181.54 (-0.01%)
MSFT   399.30 (-0.87%)
META   466.61 (-0.98%)
GOOGL   141.99 (+0.62%)
AMZN   167.76 (+0.41%)
TSLA   193.02 (-0.38%)
NVDA   674.10 (-2.94%)
NIO   6.06 (+1.68%)
AMD   162.79 (-1.75%)
BABA   75.81 (+3.65%)
T   16.98 (+0.41%)
F   12.13 (-0.98%)
MU   80.29 (-0.52%)
CGC   3.35 (-5.37%)
GE   148.36 (-0.17%)
DIS   108.02 (-1.30%)
AMC   4.61 (-1.07%)
PFE   27.53 (-0.22%)
PYPL   57.89 (-1.26%)
XOM   104.47 (+1.67%)
S&P 500   4,960.70 (-0.30%)
DOW   38,489.57 (-0.19%)
QQQ   423.61 (-0.87%)
AAPL   181.54 (-0.01%)
MSFT   399.30 (-0.87%)
META   466.61 (-0.98%)
GOOGL   141.99 (+0.62%)
AMZN   167.76 (+0.41%)
TSLA   193.02 (-0.38%)
NVDA   674.10 (-2.94%)
NIO   6.06 (+1.68%)
AMD   162.79 (-1.75%)
BABA   75.81 (+3.65%)
T   16.98 (+0.41%)
F   12.13 (-0.98%)
MU   80.29 (-0.52%)
CGC   3.35 (-5.37%)
GE   148.36 (-0.17%)
DIS   108.02 (-1.30%)
AMC   4.61 (-1.07%)
PFE   27.53 (-0.22%)
PYPL   57.89 (-1.26%)
XOM   104.47 (+1.67%)

AbCellera Biologics (ABCL) Stock Price, News & Analysis

$4.76
-0.55 (-10.36%)
(As of 12:16 PM ET)
Today's Range
$4.71
$5.25
50-Day Range
$4.91
$5.97
52-Week Range
$3.87
$8.83
Volume
1.91 million shs
Average Volume
1.38 million shs
Market Capitalization
$1.38 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.38

AbCellera Biologics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
317.5% Upside
$20.38 Price Target
Short Interest
Bearish
12.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of AbCellera Biologics in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.48) to ($0.60) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.75 out of 5 stars

Medical Sector

1293rd out of 1,856 stocks

Pharmaceutical Preparations Industry

615th out of 870 stocks


ABCL stock logo

About AbCellera Biologics Stock (NASDAQ:ABCL)

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

ABCL Stock Price History

ABCL Stock News Headlines

An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
Q4 2023 Abcellera Biologics Inc Earnings Call
Recap: AbCellera Biologics Q4 Earnings
AbCellera Reports Full Year 2023 Business Results
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
AbCellera Biologics (ABCL) Scheduled to Post Earnings on Tuesday
AbCellera Biologics: Continuing To Expand Partnerships
Techne (TECH) Q2 Earnings and Revenues Lag Estimates
Abcellera Biologics Inc (ABCL)
Baillie Gifford Adjusts Stake in AbCellera Biologics Inc
ABCL Jul 2024 7.000 put
See More Headlines
Receive ABCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/03/2023
Today
2/21/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ABCL
Fax
N/A
Employees
630
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.38
High Stock Price Target
$34.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+283.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$158.52 million
Net Margins
-256.27%
Pretax Margin
-311.24%

Debt

Sales & Book Value

Annual Sales
$485.42 million
Cash Flow
$0.67 per share
Book Value
$4.31 per share

Miscellaneous

Free Float
196,010,000
Market Cap
$1.54 billion
Optionable
Optionable
Beta
0.38

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. Carl L.G. Hansen Ph.D. (Age 49)
    CEO, President & Chairperson
    Comp: $711.47k
  • Mr. Andrew Booth M.B.A. (Age 50)
    Chief Financial Officer
    Comp: $642.42k
  • Dr. Veronique Lecault Ph.D. (Age 39)
    COO & Director
    Comp: $645.07k
  • Mr. Tryn T. Stimart Esq. (Age 54)
    J.D., Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
    Comp: $644.4k
  • Mr. Neil Aubuchon M.B.A. (Age 54)
    Chief Commercial Officer
    Comp: $684.81k
  • Marcie Thiessen CPA
    CGA, Senior Director of Finance & Accounting
  • Dr. Ester Falconer Ph.D. (Age 49)
    Chief Technology Officer
  • Josephine Hellschlienger Ph.D.
    Manager of Investor Relations
  • Kathleen Reid B.A.
    Head of Corporate Communications
  • Graham Craig M.Sc.
    Director of Corporate Development














ABCL Stock Analysis - Frequently Asked Questions

Should I buy or sell AbCellera Biologics stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ABCL shares.
View ABCL analyst ratings
or view top-rated stocks.

What is AbCellera Biologics' stock price target for 2024?

10 equities research analysts have issued twelve-month price objectives for AbCellera Biologics' shares. Their ABCL share price targets range from $6.00 to $34.00. On average, they anticipate the company's share price to reach $20.38 in the next twelve months. This suggests a possible upside of 317.5% from the stock's current price.
View analysts price targets for ABCL
or view top-rated stocks among Wall Street analysts.

How have ABCL shares performed in 2024?

AbCellera Biologics' stock was trading at $5.71 at the beginning of the year. Since then, ABCL stock has decreased by 14.5% and is now trading at $4.88.
View the best growth stocks for 2024 here
.

When is AbCellera Biologics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ABCL earnings forecast
.

How were AbCellera Biologics' earnings last quarter?

AbCellera Biologics Inc. (NASDAQ:ABCL) released its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.02. The business had revenue of $10.10 million for the quarter, compared to analysts' expectations of $12.38 million. AbCellera Biologics had a negative trailing twelve-month return on equity of 10.72% and a negative net margin of 256.27%. The company's revenue was down 78.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.02) earnings per share.

What ETFs hold AbCellera Biologics' stock?

ETFs with the largest weight of AbCellera Biologics (NASDAQ:ABCL) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM).TrueShares Technology, AI & Deep Learning ETF (LRNZ).

When did AbCellera Biologics IPO?

(ABCL) raised $356 million in an initial public offering on Friday, December 11th 2020. The company issued 23,000,000 shares at $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO.

Who are AbCellera Biologics' major shareholders?

AbCellera Biologics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (8.29%), Capital World Investors (2.88%), Federated Hermes Inc. (1.07%), FIL Ltd (0.65%), Norges Bank (0.32%) and Intellectus Partners LLC (0.31%). Insiders that own company stock include Andrew Booth, Andrew Lo, Carl L G Hansen, Holdings Ltd Thermopylae, John Hamer, John S Montalbano, Michael R Hayden and Veronique Lecault.
View institutional ownership trends
.

How do I buy shares of AbCellera Biologics?

Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ABCL) was last updated on 2/21/2024 by MarketBeat.com Staff